SBIR/STTR Research Award

PLAGUE VACCINE CANDIDATES BY A FUNCTIONAL GENOMIC SCREEN

Award identifier 72110e8c734718379a48fcea2c572557a542fd03d17f91edfd8008bc308729ddAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$133,750

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ELIANCE BIOTECHNOLOGY, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The long-term objective of our work is to produce a comprehensive set of vaccines that would effectively protect a large population against even genetically-engineered pathogens. The immediate objective of the proposal described here is to screen the whole genome of Yersinia pestis for the most potent vaccine candidates. Plague is a significant target for at least two reasons. 1) It is an extremely virulent, often lethal disease that has been suffered by humans since antiquity. 2) There is an immediate need to produce a broadly effective, safe, and inexpensive vaccine to counter the threat of bioterrorism. The immunogenic simplicity of a subunit vaccine currently under study may limit its ability to protect the diverse human population, and may render it ineffectual against a genetically-modified pathogen. Our phase I specific aims are to i) establish the informatics required to support a technically demanding, functional screen of the entire Y. pestis genome for protective antigens, ii) identify protocols for producing a complete Y. pestis gene library iii) define the optimal gene dose and design for this genome screen by testing Y. pestis genes in immune and protection assays. Our experimental approach combines three of our technologies: genetic immunization, expression library screening, and linear gene expression elements. In phase II we will apply this system to evaluate every Y. pestis gene as a PCR product in an arrayed matrix for protection of mice against infection. Positively scoring genes will constitute a portfolio of antigenic options to protect a broad population against natural and unnatural Y. pestis infections. In addition to identifying the components for a future vaccine, these protective antigens will reveal immune markers of protection, and thereby facilitate clinical validation of these as well as other potential plague vaccines.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.